Emerging Concepts in the Management and Treatment of Osteonecrosis of the Jaw

Oral and Maxillofacial Surgery Clinics of North America

Volumn 25, Issue 1, 2013, Pages 11-20

  Ruggiero, Salvatore L ^a,b,c  

^a New York Center for Orthognathic and Maxillofacial Surgery   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

Antiresorptive treatment; Bisphosphonates; Bone remodeling; BRONJ; Jaw necrosis; Osteonecrosis

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

HUMAN; JAW OSTEONECROSIS; REVIEW; RISK FACTOR;

BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; HUMANS; RISK FACTORS;

EID: 84873516261     PISSN: 10423699     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coms.2012.10.002     Document Type: Review

References (58)

1. Allen M., Burr D. Mandible matrix necrosis in beagle dogs following 3 years of daily oral bisphosphonate treatment. J Oral Maxillofac Surg 2008, 66:987-994.
2. Allen M., Kubek D., Burr D., et al. Compromised osseous healing of dental extraction sites in zolendronic acid-treated dogs. Osteoporos Int 2010, 22(2):693-702.
3. Burr D., Allen M. Mandibular necrosis in beagle dogs treated with bisphosphonates. Orthod Craniofac Res 2009, 12:221-228.
4. Taylor K., Middlefell L., Mizen K. Osteonecrosis of the jaws induced by anti-RANK ligand therapy. Br J Oral Maxillofac Surg 2010, 48:221-223.
5. Aghaloo T., Felsenfeld A., Tetradis S. Osteonecrosis of the jaw in a patient on denosumab. J Oral Maxillofac Surg 2010, 68:959-963.
6. Diz P., Lopez-Cedrun J., Arenaz J., et al. Denosumab-related osteonecrosis of the jaw. J Am Dent Assoc 2012, 143(9):981-984.
7. Stopeck A., Body J., Fujiwara Y. Denosumab versus zolendronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study. Eur J Cancer 2009, 7(2):3082-3092.
8. Wood J., Bonjean K., Ruetz S. Novel antiangiogenic effects of the bisphosphonate compound zolendronic acid. J Pharmacol Exp Ther 2002, 302:1055-1061.
9. Fournier P., Boissier S., Filleur S., et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002, 62:6538-6544.
10. Deckers M., Van Beek E., Van Der Pluijm G., et al. Dissociation of angiogenesis and osteoclastogenesis during endochondral bone formation in neonatal mice. J Bone Miner Res 2002, 17:998.
11. Landesberg R., Cozin M., Cremers S., et al. Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg 2008, 66:839-847.
12. Otto S., Pautke C., Opelz C., et al. Osteonecrosis of the jaw: effect of BP type, local concentration, and acid milieu on the pathomechanism. J Oral Maxillofac Surg 2010, 68:2837-2845.
13. Katz J., Gong Y., Salmasinia D., et al. Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw. Int J Oral Maxillofac Surg 2011, 40:605-611.
14. Nicoletti P., Cartsos V., Palaska P., et al. Genomewide pharmocogenetics of bisphosphonate-induced osteonecrosis of the jaw: the role of RBMS3. Int J Oral Maxillofac Surg 2012, 17:1-9.
15. Sarasquete M. BRONJ is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide analysis. Blood 2008, 111:2709.
16. Allen M., Pandya B., Ruggiero S. Lack of correlation between duration of osteonecrosis of the jaw and sequestra tissue morphology: what it tells us about the condition and what it means for future studies. J Oral Maxillofac Surg 2010, 68:2730-2734.
17. Allen M., Ruggiero S. Higher bone matrix density exists in only a subset of patients with bisphosphonate-related osteonecrosis of the jaw. J Oral Maxillofac Surg 2009, 67:1373-1377.
18. Marx R., Sawatari Y., Fortin M. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention and treatment. J Oral Maxillofac Surg 2005, 63:1567-1575.
19. Ruggiero S., Fantasia J., Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006, 102:433-441.
20. Ruggiero S., Mehrotra B., Rosenberg T. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004, 62:527-534.
21. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons American Association of Oral and Maxillofacial Surgeons. Position paper on bisphosphonate-related osteonecrosis of the jaw. J Oral Maxillofac Surg 2007, 65(3):369-376.
22. Ruggiero S., Dodson T., Assael L., et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws: 2009 update. J Oral Maxillofac Surg 2009, 67:2-12.
23. Fedele S., Porter S., D'Aiuto F., et al. Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series. Am J Med 2010, 123:1060-1064.
24. Durie B., Katz M., Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005, 353:99. [letter].
25. Badros A., Weikel D., Salama A. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006, 24:945-952.
26. Barasch A., Cunha-Cruz J., Curro F., et al. Risk factors for osteonecrosis of the jaws: a case-control study from the CONDOR dental PBRN. J Dent Res 2011, 90(4):439-444.
27. Hoff A., Toth B., Altundag K. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. J Clin Oncol 2006, 24:8528.
28. Bagan J., Jimenez Y., Gomez D., et al. Collagen telopeptide (serum CTX) and its relationship with size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates. Oral Oncol 2008, 44:1088-1089.
29. Kunchur R., Need A., Hughes T., et al. Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate -associated osteonecrosis of the jaws. J Oral Maxillofac Surg 2009, 67:1167-1173.
30. Kwon Y., Kim D., Obe J., et al. Correlation between serum C-terminal cross-linking telopeptide of type 1 collagen and staging of oral bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2009, 67:2644-2648.
31. Lehrer S., Montazem A., Ramanathan L., et al. Normal serum bone markers in bisphosphonate-induced osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008, 106:389-391.
32. Marx R., Cillo J., Ulloa J. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007, 65:2397-2410.
33. Rosen H., Moses A., Garber J., et al. Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 2000, 66:100-103.
34. Rosen H., Moses A., Garber J., et al. Utility of biochemical markers of bone turnover in the follow-up of patients treated with bisphosphonates. Calcif Tissue Int 1998, 63:363-368.
35. Treister N., Friedland B., Woo S. Use of cone-beam computerized tomography for evaluation of bisphosphonate-associated osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010, 109:753-764.
36. Arce K., Assael L., Weissman J., et al. Image findings in bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2009, 67(Suppl 1):75-84.
37. Chiandussi S., Biasotto M., Cavalli F., et al. Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws. Dentomaxillofac Radiol 2006, 35:236-243.
38. O'Ryan F., Khoury S., Liao W., et al. Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator. J Oral Maxillofac Surg 2009, 67:1363-1372.
39. Carlson E., Basile J. The role of surgical resection in the mangement of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2009, 67(Suppl 1):85-95.
40. Herford A., Boyne P. Reconstruction of mandibular continuity defects with bone morphogenic protein-2 (rhBMP-2). J Oral Maxillofac Surg 2008, 66:616-624.
41. Mucke T., Koschinski J., Deppe H., et al. Outcome of treatment and parameters influencing recurrence in patients with bisphosphonate-related osteonecrosis of the jaws. J Cancer Res Clin Oncol 2011, 137(5):907-913.
42. Stockman P., Vairaktaris E., Wehrhan F., et al. Osteotomy and primary wound closure in bisphosphonate-associated osteonecrosis of the jaw: a prospective clinical study with 12 months follow-up. Support Care Cancer 2009, 18:449-460.
43. Stanton D.C., Balasanian E. Outcome of surgical management of bisphosphonate-related osteonecrosis of the jaws: review of 33 surgical cases. J Oral Maxillofac Surg 2009, 67(5):943-950.
44. Freiberger J.J., Padilla-Burgos R., McGraw T., et al. What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics. J Oral Maxillofac Surg 2012, 70(7):1573-1583.
45. Curi M., Cossolin G., Koga D., et al. Treatment of avascular necrosis of the mandible in cancer patients with a history of bisphosphonate therapy by combining bone resection and autologous platelet-rich plasma: report of 3 cases. J Oral Maxillofac Surg 2007, 65:349-355.
46. Lee C., David T., Nishime M. Use of platelet-rich plasma in the management of oral bisphosphonate-associated osteonecrosis of the jaw: a report of 2 cases. J Oral Implantol 2007, 32:371-382.
47. Epstein M., Wicknick F., Eptein J., et al. Management of bisphosphonate-associated osteonecrosis: pentoxifylline and tocopherol in addition to antimicrobial therapy. An initial case series. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010, 110:593-596.
48. Harper R., Fung E. Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1-340]. J Oral Maxillofac Surg 2007, 65:573-580.
49. Cheung A., Seeman E. Teriparatide therapy for alendronate-associated osteonecrosis of the jaw. N Engl J Med 2010, 363:2473-2474.
50. Bashutski J.D., Eber R.M., Kinney J.S., et al. Teriparatide and osseous regeneration in the oral cavity. N Engl J Med 2010, 363(25):2396-2405.
51. Marx R. Pamidronate (Aredia) and zolendronate (Zometa) induced vascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003, 61:1115-1117.
52. Bi Y., Gao Y., Ehirchiou D., et al. Bisphosphonates cause osteonecrosis of the jaw-like disease in mice. Am J Pathol 2010, 177:280-290.
53. Kikuiri Y., Kim I., Yamaza T., et al. Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaws-like disease in mice. J Bone Miner Res 2010, 25:1668-1679.
54. Hokugo A., Christensen R., Chung E., et al. Increased prevalence of bisphosphonate-related osteonecrosis of the jaw with vitamin D deficiency in rats. J Bone Miner Res 2010, 25:1337-1349.
55. Lopez-Jornet P., Camacho-Alonso F., Molina-Miñano F., et al. An experimental study of bisphosphonate-induced jaw necrosis in Sprague-Dawley rats. J Oral Pathol Med 2010, 39(9):697-702.
56. Maahs M., Azambuja A.A., Campos M.M., et al. Association between bisphosphonates and jaw osteonecrosis: a study in Wistar rats. Head Neck 2011, 33(2):199-207.
57. Grbic J., Black D., Lyles K., et al. The incidence of osteonecrosis of the jaw in patients receiving 5 mgs of zolendronic acid. Data from the health outcomes and reduced incidence with zolendronic acid once yearly clinical trials program. J Am Dent Assoc 2010, 141:1365-1370.
58. Grbic J., Landesberg R., Lin S. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zolendroic acid once yearly. J Am Dent Assoc 2008, 139:32-40.